Literature DB >> 25741135

Anal cancer treatment: current status and future perspectives.

Marwan Ghosn1, Hampig Raphael Kourie1, Pamela Abdayem1, Joelle Antoun1, Dolly Nasr1.   

Abstract

Anal cancers (AC) are relatively rare tumors. Their incidence is increasing, particularly among men who have sex with other men due to widespread infection by human papilloma virus. The majority of anal cancers are squamous cell carcinomas, and they are treated according to stage. In local and locally advanced AC, concomitant chemoradiation therapy based on mitomycin C and 5-Fluorouracil (5-FU) is the current best treatment, while metastatic AC, chemotherapy with 5-FU and cisplatin remains the gold standard. There are no indications for induction or maintenance therapies in locally advanced tumors. Many novel strategies, such as targeted therapies, vaccination, immunotherapy and photodynamic therapy are in clinical trials for the treatment of AC, with promising results in some indications.

Entities:  

Keywords:  Anal cancer; Guidelines; Novel approaches; Optimum treatment; Updates

Mesh:

Substances:

Year:  2015        PMID: 25741135      PMCID: PMC4342904          DOI: 10.3748/wjg.v21.i8.2294

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  93 in total

1.  Clinical experience with chemoradiotherapy comprising S-1 plus low-dose cisplatin in a patient with stage IV anal cancer.

Authors:  Nobuhiro Nitori; Yutaro Kato; Ayu Kato; Tomoaki Deguchi; Akihiro Okada; Masayuki Kojima; Junko Kuroda; Tomohisa Kadomura; Keisuke Kubota; Nobuto Origuchi; Masato Fujisaki; Masaki Kitajima
Journal:  Anticancer Res       Date:  2011-11       Impact factor: 2.480

2.  Depth of invasion, location, and size of cancer of the anus dictate operative treatment.

Authors:  W H Schraut; C H Wang; P J Dawson; G E Block
Journal:  Cancer       Date:  1983-04-01       Impact factor: 6.860

3.  Combined modality therapy for HIV-infected patients with squamous cell carcinoma of the anus: outcomes and toxicities.

Authors:  Scott Edelman; Peter A S Johnstone
Journal:  Int J Radiat Oncol Biol Phys       Date:  2006-09-01       Impact factor: 7.038

4.  Carcinoma of the anal canal. A clinical and pathologic study of 188 cases.

Authors:  B M Boman; C G Moertel; M J O'Connell; M Scott; L H Weiland; R W Beart; L L Gunderson; R J Spencer
Journal:  Cancer       Date:  1984-07-01       Impact factor: 6.860

5.  Epidermal growth factor receptor and K-RAS status in two cohorts of squamous cell carcinomas.

Authors:  Nancy Van Damme; Philippe Deron; Nadine Van Roy; Pieter Demetter; Alain Bols; Jo Van Dorpe; Filip Baert; Jean-Luc Van Laethem; Franki Speleman; Patrick Pauwels; Marc Peeters
Journal:  BMC Cancer       Date:  2010-05-11       Impact factor: 4.430

6.  Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial.

Authors:  Jaffer A Ajani; Kathryn A Winter; Leonard L Gunderson; John Pedersen; Al B Benson; Charles R Thomas; Robert J Mayer; Michael G Haddock; Tyvin A Rich; Christopher Willett
Journal:  JAMA       Date:  2008-04-23       Impact factor: 56.272

7.  Long-term results of weekly/daily cisplatin-based chemoradiation for locally advanced squamous cell carcinoma of the anal canal.

Authors:  Cathy Eng; George J Chang; Y Nancy You; Prajnan Das; Yan Xing; Marc Delclos; Robert A Wolff; Miguel A Rodriguez-Bigas; John Skibber; Aki Ohinata; Spencer Gould; Jonathan Phillips; Christopher H Crane
Journal:  Cancer       Date:  2013-08-20       Impact factor: 6.860

8.  Outcomes of salvage surgery for squamous cell carcinoma of the anal canal.

Authors:  Dan E Schiller; Bernard J Cummings; Sundeep Rai; Lisa W Le; Linda Last; Phil Davey; Alexandra Easson; Andrew J Smith; Carol J Swallow
Journal:  Ann Surg Oncol       Date:  2007-07-20       Impact factor: 5.344

9.  Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial.

Authors:  Roger D James; Robert Glynne-Jones; Helen M Meadows; David Cunningham; Arthur Sun Myint; Mark P Saunders; Timothy Maughan; Alec McDonald; Sharadah Essapen; Martin Leslie; Stephen Falk; Charles Wilson; Simon Gollins; Rubina Begum; Jonathan Ledermann; Latha Kadalayil; David Sebag-Montefiore
Journal:  Lancet Oncol       Date:  2013-04-09       Impact factor: 41.316

10.  Salvage surgery for residual primary and locally recurrent anal squamous cell carcinoma after chemoradiotherapy in HIV-positive individuals.

Authors:  Laila Cunin; M Alfa-Wali; J Turner; M Bower; L Ion; T Allen-Mersh
Journal:  Ann Surg Oncol       Date:  2013-11-18       Impact factor: 5.344

View more
  19 in total

Review 1.  Advances in the Management of Anal Cancer.

Authors:  Diana R Julie; Karyn A Goodman
Journal:  Curr Oncol Rep       Date:  2016-03       Impact factor: 5.075

2.  Uncertainty Abounds in the World of Anal Dysplasia Screening.

Authors:  Wesley G Willeford; Laura H Bachmann
Journal:  Sex Transm Dis       Date:  2016-07       Impact factor: 2.830

3.  A combined modality therapeutic approach to metastatic anal squamous cell carcinoma with systemic chemotherapy and local therapy to sites of disease: case report and review of literature.

Authors:  Rosana Gnanajothy; Graham W Warren; Sherry Okun; Lindsay L Peterson
Journal:  J Gastrointest Oncol       Date:  2016-06

4.  From radiation osteitis to osteoradionecrosis: incidence and MR morphology of radiation-induced sacral pathologies following pelvic radiotherapy.

Authors:  Adrian J Meixel; Henrik Hauswald; Stefan Delorme; Björn Jobke
Journal:  Eur Radiol       Date:  2018-02-23       Impact factor: 5.315

5.  Comparison of definitive chemoradiation with 5-fluorouracil versus capecitabine in anal cancer.

Authors:  Yoanna Pumpalova; Margaret M Kozak; Rie von Eyben; Pamela Kunz; George Fisher; Daniel T Chang; Sigurdis Haraldsdottir
Journal:  J Gastrointest Oncol       Date:  2019-08

6.  Successful Treatment of Metastatic Anal Canal Adenocarcinoma with mFOLFOX6 + Bevacizumab.

Authors:  Mototsugu Matsunaga; Keisuke Miwa; Yosuke Oka; Sachiko Nagasu; Takahiko Sakaue; Masaru Fukahori; Tomoyuki Ushijima; Yoshito Akagi
Journal:  Case Rep Oncol       Date:  2016-04-26

7.  5-Fluorouracil upregulates cell surface B7-H1 (PD-L1) expression in gastrointestinal cancers.

Authors:  Lauren Van Der Kraak; Gaurav Goel; Rajeev Dhupar; Michael T Lotze; Krishnaveni Ramanan; Christof Kaltenmeier; Lin Zhang; Daniel P Normolle; Gordon J Freeman; Daolin Tang; Katie S Nason; Jon M Davison; James D Luketich
Journal:  J Immunother Cancer       Date:  2016-10-18       Impact factor: 13.751

8.  No additional prognostic value for MRE11 in squamous cell carcinomas of the anus treated with chemo-radiotherapy.

Authors:  Alexandra K Walker; Christiana Kartsonaki; Elena Collantes; Judith Nicholson; Duncan C Gilbert; Anne E Kiltie
Journal:  Br J Cancer       Date:  2017-06-22       Impact factor: 7.640

9.  Targeting phosphorylation of STAT3 delays tumor growth in HPV-negative anal squamous cell carcinoma mouse model.

Authors:  Lin-Lin Bu; Yi-Cun Li; Guang-Tao Yu; Jian-Feng Liu; Wei-Wei Deng; Wen-Feng Zhang; Lu Zhang; Zhi-Jun Sun
Journal:  Sci Rep       Date:  2017-07-26       Impact factor: 4.379

10.  Comprehensive multiplatform biomarker analysis of 199 anal squamous cell carcinomas.

Authors:  Brandon G Smaglo; Anteneh Tesfaye; Thorvardur R Halfdanarson; Joshua E Meyer; Jue Wang; Zoran Gatalica; Sandeep Reddy; David Arguello; Patrick M Boland
Journal:  Oncotarget       Date:  2015-12-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.